SCHEMBL1783717

SCHEMBL1783717

CCC1=C(C)C(=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12657248 0.85 GAA (0.36)
SCHEMBL4291847 0.82
SCHEMBL4199013 0.75 GAA (0.41)
SCHEMBL5392067 0.74
SCHEMBL1235274 0.73 GAA (0.36)
SCHEMBL1235273 0.73 GAA (0.36)
SCHEMBL5399357 0.72
SCHEMBL1171891 0.72
SCHEMBL1052043 0.69
SCHEMBL3951114 0.69 MEN1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114947175-A Composition for simulating tobacco flavor 尼科创业贸易有限公司 2022-08-30 CN disclosed
CN-109906042-B Composition for simulating tobacco flavor 尼科创业贸易有限公司 2022-07-01 CN disclosed
US-9550765-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-01-24 US disclosed
EP-2719698-B1 Methods for preparing aurora kinase inhibitors MILLENNIUM PHARM INC (US) 2016-10-05 EP disclosed
US-9200004-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-12-01 US disclosed
US-20150329534-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2015-11-19 US disclosed
US-20140200227-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION (US) 2014-07-17 US disclosed
US-8450533-B2 Cyclopropanation process GIVAUDAN SA (CH) 2013-05-28 US disclosed
US-8450533-B2 Cyclopropanation process GIVAUDAN SA (CH) 2013-05-28 US disclosed
US-8450533-B2 Cyclopropanation process GIVAUDAN SA (CH) 2013-05-28 US disclosed
EP-2261226-A1 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-15 EP disclosed
EP-2190803-A1 CYCLOPROPANATION PROCESS Givaudan SA (CH) 2010-06-02 EP disclosed
US-7598417-B2 Analgesics; muscular disorders; diarrhea ALLERGAN, INC. (US) 2009-10-06 US disclosed
WO-2009023980-A1 CYCLOPROPANATION PROCESS GIVAUDAN SA (CH) 2009-02-26 WO disclosed
WO-2009023980-A1 CYCLOPROPANATION PROCESS GIVAUDAN SA (CH) 2009-02-26 WO disclosed
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ALLERGAN, INC. 2008-10-16 US disclosed
US-4315032-A ANTITHROMBOGENIC AGENTS, ANTIULCER AGENTS TEITIN LIMITED (JP) 1982-02-09 US disclosed
EP-0019475-A2 Process for preparing adjacently disubstituted ketones, novel prostaglandins E1 and anti-thrombotic compositions containing them TEIJIN LIMITED (JP) 1980-11-26 EP disclosed
US-4139717-A 1,3-Dicarbonyl compounds TEIJIN LIMITED (JP) 1979-02-13 US disclosed
US-4009196-A HYPOTENSIVE AGENTS, BRONCHODILATORS, PROSTAGLANDIN ANALOGS TEIJIN LIMITED (JA) 1977-02-22 US disclosed